Join Growin Stock Community!

Atricure, inc.ATRC.US Overview

US StockHealthcare
(No presentation for ATRC)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ATRC AI Insights

ATRC Overall Performance

ATRC AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ATRC Recent Performance

-2.19%

Atricure, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ATRC PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ATRC Key Information

ATRC Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ATRC Profile

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Price of ATRC

ATRC FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ATRC Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.23
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2.91
PB Ratio
3.20
Price-to-FCF
31.54
METRIC
VALUE
vs. INDUSTRY
Gross Margin
74.98%
Net Margin
-2.14%
Revenue Growth (YoY)
14.88%
Profit Growth (YoY)
15.32%
3-Year Revenue Growth
16.87%
3-Year Profit Growth
17.39%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.23
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2.91
PB Ratio
3.20
Price-to-FCF
31.54
Gross Margin
74.98%
Net Margin
-2.14%
Revenue Growth (YoY)
14.88%
Profit Growth (YoY)
15.32%
3-Year Revenue Growth
16.87%
3-Year Profit Growth
17.39%

  • When is ATRC's latest earnings report released?

    The most recent financial report for Atricure, inc. (ATRC) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ATRC's short-term business performance and financial health. For the latest updates on ATRC's earnings releases, visit this page regularly.

  • What is the operating profit of ATRC?

    According to the latest financial report, Atricure, inc. (ATRC) reported an Operating Profit of 2.49M with an Operating Margin of 1.77% this period, representing a growth of 117.15% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ATRC's revenue growth?

    In the latest financial report, Atricure, inc. (ATRC) announced revenue of 140.5M, with a Year-Over-Year growth rate of 13.05%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does ATRC have?

    At the end of the period, Atricure, inc. (ATRC) held Total Cash and Cash Equivalents of 167.43M, accounting for 0.26 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ATRC go with three margins increasing?

    In the latest report, Atricure, inc. (ATRC) achieved the “three margins increasing” benchmark, with a gross margin of 75%%, operating margin of 1.77%%, and net margin of 1.2%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ATRC's profit trajectory and future growth potential.

  • Is ATRC's EPS continuing to grow?

    According to the past four quarterly reports, Atricure, inc. (ATRC)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.04. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ATRC?

    Atricure, inc. (ATRC)'s Free Cash Flow (FCF) for the period is 18.43M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 486.22% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.